M&A Healthcare Advisors Fall 2022 Webinar – Transaction Support Roles

The M&A Healthcare Advisors’ Fall Webinar commenced with a warm welcome extended to all attendees. Hosted by Mark Thomas, co-founder of M&A Healthcare Advisors, the event promised an insightful discussion centered around transaction Port. Joining Mark as a co-host was Andre Ulloa, another esteemed co-founder of the advisory firm. Before delving into the main agenda, Mark took a moment to introduce M&A Healthcare Advisors to those unfamiliar with their work. As a boutique M&A advisory firm focused on lower middle-market healthcare clients, the company specializes in sell-side representation, hourly M&A consulting, and expert valuations. With a wealth of experience and successful transactions under their belt, the team at M&A Healthcare Advisors understands the various elements that contribute to the seamless execution of healthcare deals. Mark proceeded to introduce the four distinguished guests who would be sharing their insights throughout the webinar: Shannon, Jack, Doug, and Mike. Each guest possessed a unique background and expertise, making them valuable contributors to the conversation. Their presence exemplified the diverse perspectives necessary for a comprehensive exploration of the topics at hand.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…